Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis Jacques Donnez, M.D., Ph.D., Paul J Dewart, M.D., Bernard Hedon, M.D., Antonio Perino, M.D., Adolf E Schindler, M.D., Joëlle Blumberg, M.D., Denis Querleu, M.D. Fertility and Sterility Volume 81, Issue 2, Pages 297-304 (February 2004) DOI: 10.1016/j.fertnstert.2003.07.013
FIGURE 1 (A) FSH, (B) LH, and (C) estradiol log linear scale plasma profiles in the two treatment groups (♦ SR 3-month; • SR 28-day). Donnez. Decapeptyl pharmacodynamics in endometriosis. Fertil Steril 2004. Fertility and Sterility 2004 81, 297-304DOI: (10.1016/j.fertnstert.2003.07.013)
FIGURE 2 Mean triptorelin ± SD concentration over time following a single IM injection of triptorelin 3-month SR (• Group A) and following three monthly IM injections of triptorelin 28-day SR (○ Group B). Donnez. Decapeptyl pharmacodynamics in endometriosis. Fertil Steril 2004. Fertility and Sterility 2004 81, 297-304DOI: (10.1016/j.fertnstert.2003.07.013)